```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable research reagent extensively used in cardiovascular studies . This Fab fragment specifically targets the glycoprotein IIb/IIIa receptor on platelets , inhibiting thrombus development. As a result, it's commonly investigated as a tool to analyze the pathways underlying thrombosis and to evaluate the efficacy of antiplatelet therapies. Distribution is typically controlled to institutional settings.
```
Abciximab Research: Utilizing C7E3 and 143653-53-6 in Studies
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently incorporates the monoclonal protein C7E3 and the chemical compound identified as 143653-53-6. These tools are essential for analyzing abciximab's biological activity, determining its therapeutic effect in different patient populations, and elucidating potential biomarkers of therapeutic success. Additional exploration leveraging these precise reagents is expected to yield valuable insights for improving clinical applications involving cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of read more c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Scientific Opportunities with the Drug Abciximab 143653-53-6 using C7E3
Recent research suggest that the drug (identified as 143653-53-6) presents significant investigative promise, particularly when paired with C7E3. Initial findings have that this combination might improve patient outcomes in multiple cardiovascular contexts. Further investigation is directed on defining the precise process of action between Abciximab and C7E3, including analysis of thrombocyte clumping and arterial safeguarding.
- Current investigation efforts intend to optimize dosing strategies.
- Laboratory approaches are being utilized to more confirm such propositions.
- Patient studies might be essential to fully assess clinical benefit.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers needing abciximab for laboratory investigations should rigorously evaluate purity and precise characteristics. This product is typically supplied as a freeze-dried powder and comprehensive analytical documentation including identity by LC-MS, potency assays, and endotoxin level testing is available. Confirm the source’s CoA outlines required values for related substances and fulfills established QC criteria .
High-Purity C7E3 Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the compound C7E3 and identified by the product number 143653-53-6, requires careful consideration of its source . This glycoprotein is commonly utilized in cell-based studies , particularly those focused on platelet clumping and clotting . Existing suppliers offer this reagent in varying amounts , typically ranging from milligram to substantial bulk amounts . Please advise reviewing the documentation of analysis to verify quality and applicability for your specific use . Furthermore , confirm the shelf life date before procuring to maintain ideal efficacy .
- Standard Purity: >95%
- Storage Conditions: -20°C or appropriate conditions
- Intended Purpose: Platelet Clumping Blocking Studies